Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.43 |
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | HTR7 | P34969 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ELAVL1 | Q15717 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HTR1E | P28566 | 1/20 | 0.36 |
| ▸ | HTR1F | P30939 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746471 | 0.91 | PTPN11 (0.43) | HTR6DRD2HTR2AHTR7BRD4 | |
| SCHEMBL8488870 | 0.87 | BRD4 (0.41) | HTR6DRD2HTR2AHTR7BRD4 | |
| SCHEMBL13745607 | 0.86 | GAK (0.43) | HTR6BRD4PTPN11 | |
| SCHEMBL1487531 | 0.85 | HTR6 (0.38) | HTR6DRD2HTR2AHTR7BRD4 | |
| SCHEMBL8488593 | 0.85 | HTR6 (0.38) | HTR6DRD2HTR2AHTR7BRD4 | |
| SCHEMBL13505060 | 0.85 | HTR6 (0.46) | HTR6DRD2HTR2AHTR7BRD4 | |
| SCHEMBL3347141 | 0.83 | HTR6 (0.38) | HTR6DRD2HTR2AHTR7BRD4 | |
| SCHEMBL13745685 | 0.82 | PTPN11 (0.42) | HTR6BRD4ELAVL1PTPN11MEN1 | |
| SCHEMBL13505483 | 0.82 | KCNH2 (0.36) | PTPN11MEN1MAPTKMT2A | |
| SCHEMBL13745691 | 0.81 | BRD4 (0.41) | HTR6DRD2HTR2AHTR7BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1749829-B1 | JNK inhibitors | EISAI R&D MAN CO LTD (JP) | 2010-11-03 | — | — | EP | disclosed |
| EP-1749829-B1 | JNK inhibitors | EISAI R&D MAN CO LTD (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1749829-A1 | JNK inhibitors | Eisai London Research Laboratories Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
| EP-1749829-A1 | JNK inhibitors | Eisai London Research Laboratories Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | NFKBIA, CHUK, MAP3K1 | HTR6 1614/4885DRD2 4289/4885HTR2A 3137/4885 |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | NFKBIA, CHUK, MAP3K1 | HTR6 1614/4885DRD2 4289/4885HTR2A 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.